The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer and BioNTech COVID-19 vaccine to now include young teens between 12 and 15 years of age. Previously, the EUA was approved for patients 16 years of age and older, however after reviewing clinical trial data that showed a 100% efficacy rate among the 2,260 clinical trial participants. Albert Bourla, Chief Executive Officer of Pfizer, stated, “We are grateful to all of our clinical trial volunteers and their families, whose courage helped make this milestone possible. Together, we hope to help bring a sense of normalcy back to young people across the country and around the world.”
Read more here.